Dynavax Technologies Corp. DVAX

NAS: DVAX | ISIN: US2681582019 14/11/2024

13,39 USD (-0,96%)

(-0,96%) 14/11/2024

Grafiek Dynavax Technologies Corp.

Grafiek Dynavax Technologies Corp.

1 dag1d -0,96%
1 week1w 2,92%
1 maand1m 24,44%
3 maanden3m 18,08%
6 maanden6m 21,29%
1 jaar1j -1,03%
5 jaar5j 129,67%

Dynavax Technologies Corp. in het nieuws

Toon enkel gratis nieuws

6 augustus 2024 · Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates · Persbericht

23 juli 2024 · Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 · Persbericht

27 juni 2024 · Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program · Persbericht

28 mei 2024 · Dynavax to Present at Upcoming Investor Conferences · Persbericht

14 mei 2024 · Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S. · Persbericht

8 mei 2024 · Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates · Persbericht

24 april 2024 · Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 · Persbericht

28 februari 2024 · Dynavax to Present at TD Cowen's 44th Annual Health Care Conference · Persbericht

22 februari 2024 · Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance · Persbericht

8 februari 2024 · Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 · Persbericht

Profiel Dynavax Technologies Corp.

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.dynavax.com

Hoofdzetel: Emeryville, California Verenigde Staten

CEO: Ryan Spencer

Werknemers: 344

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe